31 results on '"Kobinger, Gary P."'
Search Results
2. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms
- Author
-
Warfield, Kelly L., Howell, Katie A., Vu, Hong, Geisbert, Joan, Wong, Gary, Shulenin, Sergey, Sproule, Stephanie, Holtsberg, Frederick W., Leung, Daisy W., Amarasinghe, Gaya K., Swenson, Dana L., Bavari, Sina, Kobinger, Gary P., Geisbert, Thomas W., and Aman, M. Javad
- Published
- 2018
3. Intramuscular Adeno-Associated Virus–Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice
- Author
-
van Lieshout, Laura P., Soule, Geoff, Sorensen, Debra, Frost, Kathy L., He, Shihua, Tierney, Kevin, Safronetz, David, Booth, Stephanie A., Kobinger, Gary P., Qiu, Xiangguo, and Wootton, Sarah K.
- Published
- 2018
4. Relationship Between Viremia and Specific Organ Damage in Ebola Patients : A Cohort Study
- Author
-
INMI-EMERGENCY EBOV Sierra Leone Study Group, Lanini, Simone, Portella, Gina, Vairo, Francesco, Kobinger, Gary P., Pesenti, Antonio, Langer, Martin, Kabia, Soccoh, Brogiato, Giorgio, Amone, Jackson, Castilletti, Concetta, Miccio, Rossella, Capobianchi, Maria Rosaria, Strada, Gino, Zumla, Alimuddin, Di Caro, Antonino, and Ippolito, Giuseppe
- Published
- 2018
5. Structures of protective antibodies reveal sites of vulnerability on Ebola virus
- Author
-
Murin, Charles D., Fusco, Marnie L., Bornholdt, Zachary A., Qiu, Xiangguo, Olinger, Gene G., Zeitlin, Larry, Kobinger, Gary P., Ward, Andrew B., and Saphire, Erica Ollmann
- Published
- 2014
6. Impact of Systemic or Mucosal Immunity to Adenovirus on Ad-Based Ebola Virus Vaccine Efficacy in Guinea Pigs
- Author
-
Richardson, Jason S., Abou, Max C., Tran, Kaylie N., Kumar, Anand, Sahai, Beni M., and Kobinger, Gary P.
- Published
- 2011
- Full Text
- View/download PDF
7. Replication, Pathogenicity, Shedding, and Transmission of Zaire ebolavirus in Pigs
- Author
-
Kobinger, Gary P., Leung, Anders, Neufeld, James, Richardson, Jason S., Falzarano, Darryl, Smith, Greg, Tierney, Kevin, Patel, Ami, and Weingartl, Hana M.
- Published
- 2011
- Full Text
- View/download PDF
8. Stimulation of Ebola Virus Production from Persistent Infection through Activation of the Ras/MAPK Pathway
- Author
-
Strong, James E., Wong, Gary, Jones, Shane E., Grolla, Allen, Theriault, Steven, Kobinger, Gary P., and Feldmann, Heinz
- Published
- 2008
- Full Text
- View/download PDF
9. Mucosal Delivery of Adenovirus-Based Vaccine Protects against Ebola Virus Infection in Mice
- Author
-
Patel, Ami, Zhang, Yi, Croyle, Maria, Tran, Kaylie, Gray, Michael, Strong, Jim, Feldmann, Heinz, Wilson, James M., and Kobinger, Gary P.
- Published
- 2007
- Full Text
- View/download PDF
10. Role of Key Infectivity Parameters in the Transmission of Ebola Virus Makona in Macaques.
- Author
-
Vega, Marc Antoine de La, Wong, Gary, Wei, Haiyan, He, Shihua, Bello, Alexander, Fausther-Bovendo, Hugues, Audet, Jonathan, Tierney, Kevin, Tran, Kaylie, Soule, Geoff, Racine, Trina, Strong, James E, Qiu, Xiangguo, Kobinger, Gary P, and de La Vega, Marc Antoine
- Subjects
EBOLA virus disease ,VIRAL load ,EBOLA virus ,PRIMATES ,VIREMIA ,RESEARCH funding ,ANIMALS - Abstract
Many characteristics associated with Ebola virus disease remain to be fully understood. It is known that direct contact with infected bodily fluids is an associated risk factor, but few studies have investigated parameters associated with transmission between individuals, such as the dose of virus required to facilitate spread and route of infection. Therefore, we sought to characterize the impact by route of infection, viremia, and viral shedding through various mucosae, with regards to intraspecies transmission of Ebola virus in a nonhuman primate model. Here, challenge via the esophagus or aerosol to the face did not result in clinical disease, although seroconversion of both challenged and contact animals was observed in the latter. Subsequent intramuscular or intratracheal challenges suggest that viral loads determine transmission likelihood to naive animals in an intramuscular-challenge model, which is greatly facilitated in an intratracheal-challenge model where transmission from challenged to direct contact animal was observed consistently. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
- Author
-
Fausther-Bovendo, Hugues, Qiu, Xiangguo, Babuadze, George Giorgi, Azizi, Hiva, Pedersen, Jannie, Wong, Gary, and Kobinger, Gary P
- Subjects
EBOLA virus disease ,VIRAL vaccines ,LIVER ,HEMOLYSIS & hemolysins ,LYMPHOPENIA ,EBOLA virus ,ANTIBODY formation ,GLYCOPROTEINS ,RESEARCH funding ,VIRAL antibodies ,ANIMALS ,MICE - Abstract
Numerous studies have demonstrated the importance of the adaptive immunity for survival following Ebola virus (EBOV) infection. To evaluate the contribution of tissue damage to EBOV-induced immune suppression, acute liver damage or hemolysis, 2 symptoms associated with lethal EBOV infection, were chemically induced in vaccinated mice. Results show that either liver damage or hemolysis was sufficient to inhibit the host humoral response against EBOV glycoprotein and to drastically reduce the level of circulating T cells. This study thus provides a possible mechanism for the limited specific antibody production and lymphopenia in individuals with lethal hemorrhagic fever infections. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Ebola Virus Encodes Two microRNAs in Huh7-Infected Cells.
- Author
-
Diallo, Idrissa, Husseini, Zeinab, Guellal, Sara, Vion, Elodie, Ho, Jeffrey, Kozak, Robert A., Kobinger, Gary P., and Provost, Patrick
- Subjects
EBOLA virus ,MICRORNA ,REGULATOR genes ,RNA viruses ,TRANSCRIPTOMES ,VIRAL replication - Abstract
MicroRNAs (miRNAs) are important gene regulatory molecules involved in a broad range of cellular activities. Although the existence and functions of miRNAs are clearly defined and well established in eukaryotes, this is not always the case for those of viral origin. Indeed, the existence of viral miRNAs is the subject of intense controversy, especially those of RNA viruses. Here, we characterized the miRNA transcriptome of cultured human liver cells infected or not with either of the two Ebola virus (EBOV) variants: Mayinga or Makona; or with Reston virus (RESTV). Bioinformatic analyses revealed the presence of two EBOV-encoded miRNAs, miR-MAY-251 and miR-MAK-403, originating from the EBOV Mayinga and Makona variants, respectively. From the miRDB database, miR-MAY-251 and miR-MAK-403 displayed on average more than 700 potential human host target candidates, 25% of which had a confidence score higher than 80%. By RT-qPCR and dual luciferase assays, we assessed the potential regulatory effect of these two EBOV miRNAs on selected host mRNA targets. Further analysis of Panther pathways unveiled that these two EBOV miRNAs, in addition to general regulatory functions, can potentially target genes involved in the hemorrhagic phenotype, regulation of viral replication and modulation of host immune defense. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
- Author
-
Tebas, Pablo, Kraynyak, Kimberly A, Patel, Ami, Maslow, Joel N, Morrow, Matthew P, Sylvester, Albert J, Knoblock, Dawson, Gillespie, Elisabeth, Amante, Dinah, Racine, Trina, McMullan, Trevor, Jeong, Moonsup, Roberts, Christine C, Park, Young K, Boyer, Jean, Broderick, Kate E, Kobinger, Gary P, Bagarazzi, Mark, Weiner, David B, and Sardesai, Niranjan Y
- Subjects
DNA vaccines ,HUMORAL immunity ,CLINICAL trial registries ,EBOLA virus ,VOLUNTEERS ,INTERLEUKIN-12 - Abstract
Background: Nonlive vaccine approaches that are simple to deliver and stable at room temperature or 2-8°C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. Using an immunopotent DNA vaccine that generates protection from lethal EBOV challenge in small animals and nonhuman primates, we performed a clinical study to evaluate both intramuscular (IM) and novel intradermal (ID) DNA delivery.Methods: Two DNA vaccine candidates (INO-4201 and INO-4202) targeting the EBOV glycoprotein (GP) were evaluated for safety, tolerability, and immunogenicity in a phase 1 clinical trial. The candidates were evaluated alone, together, or in combination with plasmid-encoded human cytokine interleukin-12 followed by in vivo electroporation using either the CELLECTRA® IM or ID delivery devices.Results: The safety profile of all 5 regimens was shown to be benign, with the ID route being better tolerated. Antibodies to EBOV GP were generated by all 5 regimens with the fastest and steepest rise observed in the ID group. Cellular immune responses were generated with every regimen.Conclusions: ID delivery of INO-4201 was well tolerated and resulted in 100% seroreactivity after 2 doses and elicited interferon-γ T-cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations. Clinical Trials Registration. NCT02464670. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
14. The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets.
- Author
-
Wong, Gary, Leung, Anders, He, Shihua, Cao, Wenguang, Vega, Marc-Antoine De La, Griffin, Bryan D, Soule, Geoff, Kobinger, Gary P, Kobasa, Darwyn, Qiu, Xiangguo, and De La Vega, Marc-Antoine
- Subjects
EBOLA virus ,EPIDEMICS ,REVERSE genetics ,MICROBIAL virulence ,EBOLA virus disease ,ANIMAL experimentation ,COMPARATIVE studies ,IMMUNE response ,IMMUNOCOMPETENT cells ,MAMMALS ,RESEARCH methodology ,MEDICAL cooperation ,MICE ,RESEARCH ,EVALUATION research ,IMMUNOCOMPROMISED patients - Abstract
During 2013-2016, a novel isolate of Ebola virus (EBOV-Makona) caused an epidemic in West Africa. The virus was distinct from known EBOV strains (EBOV-Kikwit and EBOV-Mayinga), which were responsible for previous outbreaks in Central Africa. To investigate the pathogenicity of EBOV-Makona, we engineered and rescued an early isolate (H.sapiens-wt/GIN/2014/Makona-Gueckedou-C07, called rgEBOV-C07) using an updated reverse-genetics system. rgEBOV-C07 was found to be highly pathogenic in both the knockout mouse and ferret models, with median lethal dose values of 0.078 and 0.015 plaque-forming units, respectively. Therefore, these animals are appropriate for screening potential countermeasures against EBOV-Makona without the need for species adaptation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study.
- Author
-
Lanini, Simone, Portella, Gina, Vairo, Francesco, Kobinger, Gary P, Pesenti, Antonio, Langer, Martin, Kabia, Soccoh, Brogiato, Giorgio, Amone, Jackson, and Castilletti, Concetta
- Subjects
MUSCLE diseases ,VIREMIA ,ASPARTATE aminotransferase ,BILIRUBIN ,BIOMARKERS ,BLOOD coagulation ,CREATINE kinase ,CREATININE ,EBOLA virus disease ,PATIENT aftercare ,INTERNATIONAL agencies ,KIDNEY function tests ,LACTATE dehydrogenase ,LIVER function tests ,LONGITUDINAL method ,MEDICAL care ,MULTIPLE organ failure ,MULTIVARIATE analysis ,PATIENTS ,SURVIVAL ,ALANINE aminotransferase ,HUMAN research subjects ,PATIENT selection ,DATA analysis software ,BLOOD urea nitrogen ,INTERNATIONAL normalized ratio ,PARTIAL thromboplastin time ,DISEASE complications ,DIAGNOSIS ,DISEASE risk factors - Abstract
Background. Pathogenesis of Ebola virus disease remains poorly understood. We used concomitant determination of routine laboratory biomarkers and Ebola viremia to explore the potential role of viral replication in specific organ damage. Methods. We recruited patients with detectable Ebola viremia admitted to the EMERGENCY Organizzazione Non Governativa Organizzazione Non Lucrativa di Utilità Sociale (ONG ONLUS) Ebola Treatment Center in Sierra Leone. Repeated measure of Ebola viremia, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatine phosphokinase (CPK), lactate dehydrogenase (LDH), activated prothrombin time (aPTT), international normalized ratio (INR), creatinine, and blood urea nitrogen (BUN) were recorded. Patients were followed up from admission until death or discharge. Results. One hundred patients (49 survivors and 51 nonsurvivors) were included in the analysis. Unadjusted analysis to compare survivors and nonsurvivors provided evidence that all biomarkers were significantly above the normal range and that the extent of these abnormalities was generally higher in nonsurvivors than in survivors. Multivariable mixed-effects models provided strong evidence for a biological gradient (suggestive of a direct role in organ damage) between the viremia levels and either ALT, AST, CPK LDH, aPTT, and INR. In contrast, no direct linear association was found between viremia and either creatinine, BUN, or bilirubin. Conclusions. This study provides evidence to support that Ebola virus may have a direct role in muscular damage and imbalance of the coagulation system. We did not find strong evidence suggestive of a direct role of Ebola virus in kidney damage. The role of the virus in liver damage remains unclear, but our evidence suggests that acute severe liver injury is not a typical feature of Ebola virus disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Of?cial Classi?cation of Filoviruses.
- Author
-
Yĺmíng Bào, Amarasinghe, Gaya K., Basler, Christopher F., Bavari, Sina, Bukreyev, Alexander, Chandran, Kartik, Dolnik, Olga, Dye, John M., Ebihara, Hideki, Formenty, Pierre, Hewson, Roger, Kobinger, Gary P., Leroy, Eric M., Mühlberger, Elke, Netesov, Sergey V., Patterson, Jean L., Paweska, Janusz T., Smither, Sophie J., Ayato Takada, and Towner, Jonathan S.
- Subjects
FILOVIRIDAE ,TECHNICAL specifications ,SPECIES ,GENETICS ,EBOLA virus - Abstract
The mononegaviral family Filoviridae has eight members assigned to three genera and seven species. Until now, genus and species demarcation were based on arbitrarily chosen filovirus genome sequence divergence values ( 50% for genera, 30% for species) and arbitrarily chosen phenotypic virus or virion characteristics. Here we report filovirus genome sequence-based taxon demarcation criteria using the publicly accessible PAirwise Sequencing Comparison (PASC) tool of the US National Center for Biotechnology Information (Bethesda, MD, USA). Comparison of all available filovirus genomes in GenBank using PASC revealed optimal genus demarcation at the 55-58% sequence diversity threshold range for genera and at the 23-36% sequence diversity threshold range for species. Because these thresholds do not change the current official filovirus classification, these values are now implemented as filovirus taxon demarcation criteria that may solely be used for filovirus classification in case additional data are absent. A near-complete, coding-complete, or complete filovirus genome sequence will now be required to allow official classification of any novel "filovirus." Classification of filoviruses into existing taxa or determining the need for novel taxa is now straightforward and could even become automated using a presented algorithm/flowchart rooted in RefSeq (type) sequences. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Diagnosis and management of Ebola samples in the laboratory.
- Author
-
de La Vega, Marc-Antoine, Bello, Alexander, Chaillet, Pascale, and Kobinger, Gary P.
- Subjects
PREVENTION of epidemics ,COLLECTION & preservation of biological specimens ,EBOLA virus disease ,SYSTEM analysis ,MOBILE hospitals ,EBOLA virus ,EQUIPMENT & supplies - Abstract
The magnitude of the 2014–2016 West African Ebola virus outbreak has highlighted the importance of immediate and rapid deployment of control measures in affected areas. While many prophylactic and therapeutic options entered clinical trials in the past two years, larger use to impact on Ebola spread will not be possible until at least one product meets final approval by regulatory agencies. Control of the West African outbreak was achieved almost entirely by breaking chain of transmissions through case identification and specialized treatment, communication, safe burials and other proven methods. To achieve this in a timely manner, epidemiologists and medical teams are working in concert with laboratories to identify infected individuals and provide care within Ebola treatment units. Herein, we review an outbreak response workflow from the point of view of mobile laboratories and summarize methods that have been used by them during the West African Ebola virus outbreak of 2014–2016. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
18. A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.
- Author
-
McCarthy, Stephen D. S., Majchrzak-Kita, Beata, Racine, Trina, Kozlowski, Hannah N., Baker, Darren P., Hoenen, Thomas, Kobinger, Gary P., Fish, Eleanor N., and Branch, Donald R.
- Subjects
TREATMENT of Ebola virus diseases ,INTERFERON beta 1b ,EBOLA virus ,COMBINATION drug therapy ,ANTIVIRAL agents ,VIRAL replication ,PREVENTION - Abstract
To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). While a number of candidate drugs have shown limited efficacy in vitro and/or in non-human primate studies, differences in experimental methodologies make it difficult to compare their therapeutic effectiveness. Using an in vitro model of Ebola Zaire replication with transcription-competent virus like particles (trVLPs), requiring only level 2 biosafety containment, we compared the activities of the type I interferons (IFNs) IFN-α and IFN-ß, a panel of viral polymerase inhibitors (lamivudine (3TC), zidovudine (AZT) tenofovir (TFV), favipiravir (FPV), the active metabolite of brincidofovir, cidofovir (CDF)), and the estrogen receptor modulator, toremifene (TOR), in inhibiting viral replication in dose-response and time course studies. We also tested 28 two- and 56 three-drug combinations against Ebola replication. IFN-α and IFN-ß inhibited viral replication 24 hours post-infection (IC
50 0.038μM and 0.016μM, respectively). 3TC, AZT and TFV inhibited Ebola replication when used alone (50–62%) or in combination (87%). They exhibited lower IC50 (0.98–6.2μM) compared with FPV (36.8μM), when administered 24 hours post-infection. Unexpectedly, CDF had a narrow therapeutic window (6.25–25μM). When dosed >50μM, CDF treatment enhanced viral infection. IFN-ß exhibited strong synergy with 3TC (97.3% inhibition) or in triple combination with 3TC and AZT (95.8% inhibition). This study demonstrates that IFNs and viral polymerase inhibitors may have utility in EVD. We identified several 2 and 3 drug combinations with strong anti-Ebola activity, confirmed in studies using fully infectious ZEBOV, providing a rationale for testing combination therapies in animal models of lethal Ebola challenge. These studies open up new possibilities for novel therapeutic options, in particular combination therapies, which could prevent and treat Ebola infection and potentially reduce drug resistance. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
19. Ebolavirus Evolution: Past and Present.
- Author
-
de La Vega, Marc-Antoine, Stein, Derek, and Kobinger, Gary P
- Subjects
EBOLA virus ,NEGATIVE-strand RNA viruses ,EBOLA virus disease ,FILOVIRIDAE ,RNA viruses - Abstract
The past year has marked the most devastating Ebola outbreak the world has ever witnessed, with over 28,000 cases and over 11,000 deaths. Ebola virus (EBOV) has now been around for almost 50 years. In this review, we discuss past and present outbreaks of EBOV and how those variants evolved over time. We explore and discuss selective pressures that drive the evolution of different Ebola variants, and how they may modify the efficacy of therapeutic treatments and vaccines currently being developed. Finally, given the unprecedented size and spread of the outbreak, as well as the extended period of replication in human hosts, specific attention is given to the 2014–2015 West African outbreak variant (Makona). [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb.
- Author
-
Xiangguo Qiu, Audet, Jonathan, Wong, Gary, Fernando, Lisa, Bello, Alexander, Pillet, Stéphane, Alimonti, Judie B., and Kobinger, Gary P.
- Subjects
IMMUNE response ,IMMUNOLOGY ,IMMUNOGLOBULINS ,VIRUS diseases ,CERCOPITHECIDAE - Abstract
Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exposure, respectively. The survivors demonstrated EBOV-GP-specific humoral and cell-mediated immune responses. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is sufficient to protect survivors against a subsequent exposure, animals that survived the initial challenge were rechallenged at 10 or 13 weeks after the initial challenge. The animals rechallenged at 10 weeks all survived whereas 4 of 6 animals survived a rechallenge at 13 weeks. The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease.
- Author
-
de La Vega, Marc-Antoine and Kobinger, Gary P
- Subjects
- *
EBOLA virus disease , *VESICULAR stomatitis , *VIRAL vaccines , *HUMORAL immunity , *ADENOVIRUS diseases , *EBOLA virus , *ANIMALS , *RNA viruses , *STOMATITIS , *BLIND experiment - Published
- 2020
- Full Text
- View/download PDF
22. Altered microRNA Transcriptome in Cultured Human Liver Cells upon Infection with Ebola Virus.
- Author
-
Diallo, Idrissa, Ho, Jeffrey, Laffont, Benoit, Laugier, Jonathan, Benmoussa, Abderrahim, Lambert, Marine, Husseini, Zeinab, Soule, Geoff, Kozak, Robert, Kobinger, Gary P., Provost, Patrick, and Burkovski, Andreas
- Subjects
NON-coding RNA ,MICRORNA ,EBOLA virus ,LIVER cells ,RNA sequencing ,VIRUS diseases - Abstract
Ebola virus (EBOV) is a virulent pathogen, notorious for inducing life-threatening hemorrhagic fever, that has been responsible for several outbreaks in Africa and remains a public health threat. Yet, its pathogenesis is still not completely understood. Although there have been numerous studies on host transcriptional response to EBOV, with an emphasis on the clinical features, the impact of EBOV infection on post-transcriptional regulatory elements, such as microRNAs (miRNAs), remains largely unexplored. MiRNAs are involved in inflammation and immunity and are believed to be important modulators of the host response to viral infection. Here, we have used small RNA sequencing (sRNA-Seq), qPCR and functional analyses to obtain the first comparative miRNA transcriptome (miRNome) of a human liver cell line (Huh7) infected with one of the following three EBOV strains: Mayinga (responsible for the first Zaire outbreak in 1976), Makona (responsible for the West Africa outbreak in 2013–2016) and the epizootic Reston (presumably innocuous to humans). Our results highlight specific miRNA-based immunity pathways and substantial differences between the strains beyond their clinical manifestation and pathogenicity. These analyses shed new light into the molecular signature of liver cells upon EBOV infection and reveal new insights into miRNA-based virus attack and host defense strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014
- Author
-
Kuhn, Jens H., Andersen, Kristian G., Baize, Sylvain, Bào, Yīmíng, Bavari, Sina, Berthet, Nicolas, Blinkova, Olga, Brister, J. Rodney, Clawson, Anna N., Fair, Joseph, Gabriel, Martin, Garry, Robert F., Gire, Stephen K., Goba, Augustine, Gonzalez, Jean-Paul, Günther, Stephan, Happi, Christian T., Jahrling, Peter B., Kapetshi, Jimmy, Kobinger, Gary, Kugelman, Jeffrey R., Leroy, Eric M., Maganga, Gael Darren, Mbala, Placide K., Moses, Lina M., Muyembe-Tamfum, Jean-Jacques, N’Faly, Magassouba, Nichol, Stuart T., Omilabu, Sunday A., Palacios, Gustavo, Park, Daniel J., Paweska, Janusz T., Radoshitzky, Sheli R., Rossi, Cynthia A., Sabeti, Pardis C., Schieffelin, John S., Schoepp, Randal J., Sealfon, Rachel, Swanepoel, Robert, Towner, Jonathan S., Wada, Jiro, Wauquier, Nadia, Yozwiak, Nathan L., and Formenty, Pierre
- Subjects
Ebola ,Ebola virus ,ebolavirus ,filovirid ,filovirus ,genome annotation ,Lomela ,Lokolia ,Makona ,mononegavirad ,mononegavirus ,virus classification ,virus isolate ,virus nomenclature ,virus strain ,virus taxonomy ,virus variant - Abstract
In 2014, Ebola virus (EBOV) was identified as the etiological agent of a large and still expanding outbreak of Ebola virus disease (EVD) in West Africa and a much more confined EVD outbreak in Middle Africa. Epidemiological and evolutionary analyses confirmed that all cases of both outbreaks are connected to a single introduction each of EBOV into human populations and that both outbreaks are not directly connected. Coding-complete genomic sequence analyses of isolates revealed that the two outbreaks were caused by two novel EBOV variants, and initial clinical observations suggest that neither of them should be considered strains. Here we present consensus decisions on naming for both variants (West Africa: “Makona”, Middle Africa: “Lomela”) and provide database-compatible full, shortened, and abbreviated names that are in line with recently established filovirus sub-species nomenclatures.
- Published
- 2014
- Full Text
- View/download PDF
24. Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names
- Author
-
Kuhn, Jens H., Andersen, Kristian G., Bào, Yīmíng, Bavari, Sina, Becker, Stephan, Bennett, Richard S., Bergman, Nicholas H., Blinkova, Olga, Bradfute, Steven, Brister, J. Rodney, Bukreyev, Alexander, Chandran, Kartik, Chepurnov, Alexander A., Davey, Robert A., Dietzgen, Ralf G., Doggett, Norman A., Dolnik, Olga, Dye, John M., Enterlein, Sven, Fenimore, Paul W., Formenty, Pierre, Freiberg, Alexander N., Garry, Robert F., Garza, Nicole L., Gire, Stephen K., Gonzalez, Jean-Paul, Griffiths, Anthony, Happi, Christian T., Hensley, Lisa E., Herbert, Andrew S., Hevey, Michael C., Hoenen, Thomas, Honko, Anna N., Ignatyev, Georgy M., Jahrling, Peter B., Johnson, Joshua C., Johnson, Karl M., Kindrachuk, Jason, Klenk, Hans-Dieter, Kobinger, Gary, Kochel, Tadeusz J., Lackemeyer, Matthew G., Lackner, Daniel F., Leroy, Eric M., Lever, Mark S., Mühlberger, Elke, Netesov, Sergey V., Olinger, Gene G., Omilabu, Sunday A., Palacios, Gustavo, Panchal, Rekha G., Park, Daniel J., Patterson, Jean L., Paweska, Janusz T., Peters, Clarence J., Pettitt, James, Pitt, Louise, Radoshitzky, Sheli R., Ryabchikova, Elena I., Saphire, Erica Ollmann, Sabeti, Pardis C., Sealfon, Rachel, Shestopalov, Aleksandr M., Smither, Sophie J., Sullivan, Nancy J., Swanepoel, Robert, Takada, Ayato, Towner, Jonathan S., van der Groen, Guido, Volchkov, Viktor E., Volchkova, Valentina A., Wahl-Jensen, Victoria, Warren, Travis K., Warfield, Kelly L., Weidmann, Manfred, and Nichol, Stuart T.
- Subjects
Bundibugyo virus ,cDNA clone ,cuevavirus ,Ebola ,Ebola virus ,ebolavirus ,filovirid ,filovirus ,genome annotation ,ICTV ,International Committee on Taxonomy of Viruses ,Lloviu virus ,Marburg virus ,marburgvirus ,mononegavirad ,mononegavirus ,Ravn virus ,RefSeq ,Reston virus ,reverse genetics ,Sudan virus ,Taï Forest virus ,virus classification ,virus isolate ,virus nomenclature ,virus strain ,virus taxonomy ,virus variant - Abstract
Sequence determination of complete or coding-complete genomes of viruses is becoming common practice for supporting the work of epidemiologists, ecologists, virologists, and taxonomists. Sequencing duration and costs are rapidly decreasing, sequencing hardware is under modification for use by non-experts, and software is constantly being improved to simplify sequence data management and analysis. Thus, analysis of virus disease outbreaks on the molecular level is now feasible, including characterization of the evolution of individual virus populations in single patients over time. The increasing accumulation of sequencing data creates a management problem for the curators of commonly used sequence databases and an entry retrieval problem for end users. Therefore, utilizing the data to their fullest potential will require setting nomenclature and annotation standards for virus isolates and associated genomic sequences. The National Center for Biotechnology Information’s (NCBI’s) RefSeq is a non-redundant, curated database for reference (or type) nucleotide sequence records that supplies source data to numerous other databases. Building on recently proposed templates for filovirus variant naming [
( )/ / / / - ], we report consensus decisions from a majority of past and currently active filovirus experts on the eight filovirus type variants and isolates to be represented in RefSeq, their final designations, and their associated sequences. - Published
- 2014
- Full Text
- View/download PDF
25. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp.
- Author
-
Wong, Gary, Bienes, Kathrina Mae, XIII, Ara, Fausther-Bovendo, Hugues, and Kobinger, Gary P.
- Subjects
- *
MONOCLONAL antibodies , *EBOLA virus , *RANDOMIZED controlled trials , *IMMUNOGLOBULINS , *AUTOIMMUNE diseases , *COMMUNICABLE diseases - Abstract
In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013–2016 West Africa outbreak. This review recounts the history of a candidate mAb treatment, ZMapp, beginning with its emergency use in the 2013–2016 outbreak and advancing to randomized controlled trials into the 2018–2020 African outbreak. We end with a brief discussion of the hurdles and promise toward mAb therapeutic use against infectious disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease.
- Author
-
Kozak, Robert, Shihua He, Kroeker, Andrea, de La Vega, Marc-Antoine, Audet, Jonathan, Wong, Gary, Urfano, Chantel, Antonation, Kym, Embury-Hyatt, Carissa, Kobinger, Gary P., and Xiangguo Qiu
- Subjects
- *
FERRET , *EBOLA virus , *FILOVIRIDAE , *HEMORRHAGIC fever , *RNA viruses - Abstract
Bundibugyo virus (BDBV) is the etiological agent of a severe hemorrhagic fever in humans with a case-fatality rate ranging from 25 to 36%. Despite having been known to the scientific and medical communities for almost 1 decade, there is a dearth of studies on this pathogen due to the lack of a small animal model. Domestic ferrets are commonly used to study other RNA viruses, including members of the order Mononegavirales. To investigate whether ferrets were susceptible to filovirus infections, ferrets were challenged with a clinical isolate of BDBV. Animals became viremic within 4 days and succumbed to infection between 8 and 9 days, and a petechial rash was observed with moribund ferrets. Furthermore, several hallmarks of human filoviral disease were recapitulated in the ferret model, including substantial decreases in lymphocyte and platelet counts and dysregulation of key biochemical markers related to hepatic/renal function, as well as coagulation abnormalities. Virological, histopathological, and immunohistochemical analyses confirmed uncontrolled BDBV replication in the major organs. Ferrets were also infected with Ebola virus (EBOV) to confirm their susceptibility to another filovirus species and to potentially establish a virus transmission model. Similar to what was seen with BDBV, important hallmarks of human filoviral disease were observed in EBOV-infected ferrets. This study demonstrates the potential of this small animal model for studying BDBV and EBOV using wild-type isolates and will accelerate efforts to understand filovirus pathogenesis and transmission as well as the development of specific vaccines and antivirals. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.
- Author
-
Tran, Erin E. H., Nelson, Elizabeth A., Bonagiri, Pranay, Simmons, James A., Shoemaker, Charles J., Schmaljohn, Connie S., Kobinger, Gary P., Zeitlin, Larry, Subramaniam, Sriram, and White, Judith M.
- Subjects
- *
EBOLA virus , *MONOCLONAL antibodies , *GLYCOPROTEINS , *CELL culture , *VIRUS-like particles - Abstract
ZMapp, a cocktail of three monoclonal antibodies (MAbs; c2G4, c4G7, and c13C6) against the ebolavirus (EBOV) glycoprotein (GP), shows promise for combatting outbreaks of EBOV, as occurred in West Africa in 2014. Prior studies showed that Fabs from these MAbs bind a soluble EBOV GP ectodomain and that MAbs c2G4 and c4G7, but not c13C6, neutralize infections in cell cultures. Using cryo-electron tomography, we extended these findings by characterizing the structures of c2G4, c4G7, and c13C6 IgGs bound to native, full-length GP from the West African 2014 isolate embedded in filamentous viruslike particles (VLPs). As with the isolated ectodomain, c13C6 bound to the glycan cap, whereas c2G4 and c4G7 bound to the base region of membrane-bound GP. The tomographic data suggest that all three MAbs bind with high occupancy and that the base-binding antibodies can potentially bridge neighboring GP spikes. Functional studies indicated that c2G4 and c4G7, but not c13C6, competitively inhibit entry of VLPs bearing EBOV GP into the host cell cytoplasm, without blocking trafficking of VLPs to NPC1+ endolysosomes, where EBOV fuses. Moreover, c2G4 and c4G7 bind to and can block entry mediated by the primed (19-kDa) form of GP without impeding binding of the C-loop of NPC1, the endolysosomal receptor for EBOV. The most likely mode of action of c2G4 and c4G7 is therefore by inhibiting conformational changes in primed, NPC1-bound GP that initiate fusion between the viral and target membranes, similar to the action of certain broadly neutralizing antibodies against influenza hemagglutinin and HIV Env. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. Development and Characterization of a Guinea Pig-Adapted Sudan Virus.
- Author
-
Gary Wong, Shihua He, Haiyan Wei, Andrea Kroeker, Jonathan Audet, Anders Leung, Todd Cutts, Jill Graham, Darwyn Kobasa, Carissa Embury-Hyatt, Kobinger, Gary P., and Xiangguo Qiu
- Subjects
- *
EBOLA virus , *HEMORRHAGIC fever , *ANIMAL models in research , *IMMUNOHISTOCHEMISTRY , *EPIDEMICS - Abstract
Infections with Sudan virus (SUDV), a member of the genus Ebolavirus, result in a severe hemorrhagic fever with a fatal outcome in over 50% of human cases. The paucity of prophylactics and therapeutics against SUDV is attributed to the lack of a small-animal model to screen promising compounds. By repeatedly passaging SUDV within the livers and spleens of guinea pigs in vivoa; guinea pig-adapted SUDV variant (SUDV-GA) uniformly lethal to these animals, with a 50% lethal dose (LD50) of 5.3 x 10-2 50% tissue culture infective doses (TCID50), was developed. Animals infected with SUDV-GA developed high viremia and died between 9 and 14 days postinfection. Several hallmarks of SUDV infection, including lymphadenopathy, increased liver enzyme activities, and coagulation abnormalities, were observed. Virological analyses and gross pathology, histopathology, and immunohistochemistry findings indicate that SUDV-GA replicates in the livers and spleens of infected animals similarly to SUDV infections in nonhuman primates. These developments will accelerate the development of specific medical countermeasures in preparation for a future disease outbreak due to SUDV. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. Blood kinetics of Ebola virus in survivors and nonsurvivors.
- Author
-
Lanini, Simone, Portella, Gina, Vairo, Francesco, Kobinger, Gary P, Pesenti, Antonio, Langer, Martin, Kabia, Soccoh, Brogiato, Giorgio, Amone, Jackson, Castilletti, Concetta, Miccio, Rossella, Zumla, Alimuddin, Capobianchi, Maria Rosaria, Di Caro, Antonino, Strada, Gino, Ippolito, Giuseppe, and INMI-EMERGENCY EBOV Sierra Leone Study Group
- Subjects
- *
COMPARATIVE studies , *EBOLA virus disease , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *EVALUATION research , *RANDOMIZED controlled trials , *PREDICTIVE tests , *EBOLA virus , *VIREMIA , *DIAGNOSIS - Abstract
Background: Infection with Ebola virus (EBOV) results in a life-threatening disease, with reported mortality rates between 50%-70%. The factors that determine patient survival are poorly understood; however, clinical observations indicate that EBOV viremia may be associated with fatal outcome. We conducted a study of the kinetics of Zaire EBOV viremia in patients with EBOV disease (EVD) who were managed at an Ebola Treatment Centre in Sierra Leone during the recent West African outbreak.Methods: Data from 84 EVD patients (38 survivors, 46 nonsurvivors) were analyzed, and EBOV viremia was quantified between 2 and 13 days after symptom onset. Time since symptom onset and clinical outcome were used as independent variables to compare EBOV viral kinetics in survivors and nonsurvivors.Results: In all patients, EBOV viremia kinetics was a quadratic function of time; however, EBOV viremia was 0.94 logarithm (log) copies per ml (cp/ml) (P = 0.011) higher in nonsurvivors than in survivors from day 2 after the onset of symptoms. Survivors reached peak viremia levels at an earlier time after symptom onset than nonsurvivors (day 5 versus day 7) and had lower mean peak viremia levels compared with nonsurvivors (7.46 log cp/ml; 95% CI, 7.17-7.76 vs. 8.60 log cp/ml; 95% CI, 8.27-8.93). Before reaching peak values, EBOV viremia similarly increased both in survivors and nonsurvivors; however, the decay of viremia after the peak was much stronger in survivors than in nonsurvivors.Conclusion: Our results demonstrate that plasma concentrations of EBOV are markedly different between survivors and nonsurvivors at very early time points after symptom onset and may be predicative of outcome. Further studies focused on the early phase of the disease will be required to identify the causal and prognostic factors that determine patient outcome.Funding: Italian Ministry of Health; Italian Ministry of Foreign Affairs; EMERGENCY's private donations; and Royal Engineers for DFID-UK. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
30. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution.
- Author
-
de La Vega, Marc-Antoine, Caleo, Grazia, Audet, Jonathan, Xiangguo Qiu, Kozak, Robert A., Brooks, James I., Kern, Steven, Wolz, Anja, Sprecher, Armand, Greig, Jane, Lokuge, Kamalini, Kargbo, David K., Kargbo, Brima, Di Caro, Antonino, Grolla, Allen, Kobasa, Darwyn, Strong, James E., Ippolito, Giuseppe, Van Herp, Michel, and Kobinger, Gary P.
- Subjects
- *
VIRAL load , *EBOLA virus disease , *DIAGNOSIS , *POLYMERASE chain reaction , *DISEASE outbreaks , *VIREMIA , *STATISTICAL correlation , *IMMUNOGLOBULIN G , *BIOLOGICAL models , *IMMUNOGLOBULINS , *RESEARCH funding , *VIRAL antibodies , *EBOLA virus - Abstract
Background: Ebola virus (EBOV) causes periodic outbreaks of life-threatening EBOV disease in Africa. Historically, these outbreaks have been relatively small and geographically contained; however, the magnitude of the EBOV outbreak that began in 2014 in West Africa has been unprecedented. The aim of this study was to describe the viral kinetics of EBOV during this outbreak and identify factors that contribute to outbreak progression.Methods: From July to December 2014, one laboratory in Sierra Leone processed over 2,700 patient samples for EBOV detection by quantitative PCR (qPCR). Viremia was measured following patient admission. Age, sex, and approximate time of symptom onset were also recorded for each patient. The data was analyzed using various mathematical models to find trends of potential interest.Results: The analysis revealed a significant difference (P = 2.7 × 10(-77)) between the initial viremia of survivors (4.02 log10 genome equivalents [GEQ]/ml) and nonsurvivors (6.18 log10 GEQ/ml). At the population level, patient viral loads were higher on average in July than in November, even when accounting for outcome and time since onset of symptoms. This decrease in viral loads temporally correlated with an increase in circulating EBOV-specific IgG antibodies among individuals who were suspected of being infected but shown to be negative for the virus by PCR.Conclusions: Our results indicate that initial viremia is associated with outcome of the individual and outbreak duration; therefore, care must be taken in planning clinical trials and interventions. Additional research in virus adaptation and the impacts of host factors on EBOV transmission and pathogenesis is needed. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
31. Establishment and Characterization of a Lethal Mouse Model for the Angola Strain of Marburg Virus.
- Author
-
Xiangguo Qiu, Gary Wong, Audet, Jonathan, Cutts, Todd, Niu, Yulian, Booth, Stephanie, and Kobinger, Gary P.
- Subjects
- *
MARBURG virus , *EBOLA virus , *MARBURG virus disease , *VIREMIA , *SEVERE combined immunodeficiency , *LABORATORY mice - Abstract
Infections with Marburg virus (MARV) and Ebola virus (EBOV) cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with fatality rates up to 90%. A number of experimental vaccine and treatment platforms have previously been shown to be protective against EBOV infection. However, the rate of development for prophylactics and therapeutics against MARV has been lower in comparison, possibly because a small-animal model is not widely available. Here we report the development of a mouse model for studying the pathogenesis of MARV Angola (MARV/Ang), the most virulent strain of MARV. Infection with the wild-type virus does not cause disease in mice, but the adapted virus (MARV/Ang-MA) recovered from liver homogenates after 24 serial passages in severe combined immunodeficient (SCID) mice caused severe disease when administered intranasally (i.n.) or intraperitoneally (i.p.). The median lethal dose (LD50) was determined to be 0.015 50% TCID50 (tissue culture infective dose) of MARV/Ang-MA in SCID mice, and i.p. infection at a dose of 1,000×LD50 resulted in death between 6 and 8 days postinfection in SCID mice. Similar results were obtained with immunocompetent BALB/c and C57BL/6 mice challenged i.p. with 2,000×LD50 of MARV/Ang-MA. Virological and pathological analyses of MARV/Ang-MA-infected BALB/c mice revealed that the associated pathology was reminiscent of observations made in NHPs with MARV/Ang. MARV/Ang-MA-infected mice showed most of the clinical hallmarks observed with Marburg hemorrhagic fever, including lymphopenia, thrombocytopenia, marked liver damage, and uncontrolled viremia. Virus titers reached 108 TCID50/ml in the blood and between 106 and 1010 TCID50/g tissue in the intestines, kidney, lungs, brain, spleen, and liver. This model provides an important tool to screen candidate vaccines and therapeutics against MARV infections. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.